| Compound | Dulaglutide |
|---|---|
| Category | GLP-1 receptor agonist |
| Class | GLP-1 and Incretin Therapies |
| Evidence tier | Approved medicine |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Dulaglutide — a glp-1 receptor agonist — sits in the "Approved medicine" tier of this catalog. This compound exists as an approved medicine in at least one major jurisdiction. Approval applies to specific, labeled indications and to the regulated product — not to compounded or research-grade copies.
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes (Trulicity). Two GLP-1 molecules are linked to a modified antibody fragment, extending the half-life to roughly 4–5 days.
Mechanism of Action
Dulaglutide consists of two GLP-1 analog chains fused to an Fc fragment engineered to resist DPP-4 degradation and mediate albumin interaction. The result is sustained GLP-1 receptor activation with weekly dosing and standard class pharmacology on glucose and appetite.
Research and Evidence
The AWARD program established glycemic efficacy versus comparators in type 2 diabetes, and the REWIND cardiovascular outcomes trial (n=9,901) showed a reduction in major adverse cardiovascular events in a broad population of patients with type 2 diabetes.
Safety and Side Effects
Gastrointestinal effects predominate; warnings include pancreatitis, gallbladder events, and the class medullary thyroid carcinoma/MEN2 contraindication.
Frequently Asked Questions
What is the evidence tier of Dulaglutide?
Dulaglutide is graded "Approved medicine" on this site. This compound exists as an approved medicine in at least one major jurisdiction. Approval applies to specific, labeled indications and to the regulated product — not to compounded or research-grade copies.
Is Dulaglutide an approved medicine?
Dulaglutide exists as an approved medicine in at least one major jurisdiction — but approval covers the regulated product and its labeled indications only. Compounded or research-grade versions of the same molecule are not the approved product.
Where can I read the primary studies for Dulaglutide?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- Gerstein HC, et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND). Lancet 2019. [source]
- ClinicalTrials.gov — registered dulaglutide studies. [source]
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.